RESULTS	Both groups improved , but the authors observed no significant difference between IVIg and placebo patients regarding the primary endpoint , the mean change in the Z-score of the individually chosen targeted neurologic deficit ( the most affected system ) from baseline to 12 weeks ( p = 0.89 ) .\